Pipeline
Through joint collaborations with top pharmaceutical companies and research institutions, KREX has been used to identify autoantibody biomarkers for commercial diagnostics and screening applications. In addition, KREX has also been used to identify biologics with therapeutics potential.
Stage
Project
Pilot
Candidate id
Validation
Clinical Trial
Commercialisation
Companion Diagnostics
Cancer Immunotherapy PD1 inhibitor
Autoimmune Disease Drug 1
Autoimmune Disease Drug 2
Disease Diagnostics
Melanoma
NSCLC
Gastric Cancer
Breast Cancer
Therapeutic Autoantibodies
Rheumatoid Arthritis – A
Autism
Lupus
Parkinson’s
Aging
Rheumatoid Arthritis – B
FEATURED PRODUCTS
IMMUNOME™
High-throughput platform of 1600+
immunomodulatory proteins
CTA array
High-throughput protein array of
200+ cancer-testis antigens
Custom array
Flexible miniaturised format for
high-throughput screening
1996 – 2018 © Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361
1996 – 2018 © Sengenics All rights reserved
